

# A small amount of inhaled nitric oxide does not increase lung diffusing capacity

G.S. Zavorsky and J.M. Murias

ABSTRACT: The aim of the present study was to determine: 1) whether 40–50 ppm nitric oxide (NO) increases diffusing capacity of the lung for NO (DL,NO) and carbon monoxide (DL,CO), membrane diffusing capacity for CO (Dm,CO) and pulmonary capillary blood volume (Vc); 2) the actual number of tests required to provide a reasonable estimate of DL,NO, DL,CO, Dm,CO and Vc; and 3) repeatability of these parameters using the single-breath DL,NO–DL,CO method.

In total, 31 subjects performed five single-breath hold manoeuvres at rest, inhaling  $43\pm3$  ppm NO together with a standard diffusion mixture.

DL,NO (Dm,CO) remained unchanged from the first to fifth trial. However, compared with the first trial, DL,CO and Vc had decreased by the fourth (-4 $\pm$ 5%; 95% confidence interval (CI)=-5–-2%) and third trial (-5 $\pm$ 7%; 95% CI=-7–-2%), respectively. Repeatability over five trials was 17, 3 and 7 mL·min<sup>-1</sup>·mmHg<sup>-1</sup> for DL,NO, DL,CO and Dm,CO, respectively, and 13 mL for Vc when Dm,CO=DL,NO/2.42.

In conclusion, nitric oxide inhaled during sequential single-breath manoeuvres has no effect on diffusing capacity of the lung for nitric oxide and, thus, membrane diffusing capacity for carbon monoxide. Since more than two and three trials will lower pulmonary capillary blood volume and diffusing capacity of the lung for carbon monoxide, respectively, the average value of only two properly performed trials is suggested.

#### KEYWORDS: Diffusing capacity, nitric oxide, repeatability

he equation of the diffusing capacity of the lung for carbon monoxide (*DL*,CO) has been classically described as:

$$1/D_{L,CO} = (1/D_{m,CO}) + (1/\Theta CO \cdot V_c)$$
 (1)

where *D*m,CO represents pulmonary membrane diffusing capacity for carbon monoxide (CO) and ΘCO is the specific blood transfer conductance for CO. Vc represents pulmonary capillary blood volume [1]. Membrane resistance (1/Dm,CO) and red cell resistance  $(1/\Theta CO \cdot V_c)$  usually contribute equally to the overall diffusive resistance across the lung [2], although this has been debated [3]. To obtain Dm,CO and Vc, DL,CO has been traditionally measured at two different levels of alveolar oxygen tension (PA,O<sub>2</sub>), ~13.3-16.0 kPa (~100–120 mmHg) and ~79.8 kPa (~600 mmHg). For each level of  $PA_{,O_2}$ ,  $1/DL_{,CO}$  is then plotted on the y-axis and  $1/\Theta CO$  is plotted on the x-axis. A line is then drawn through two points and the xintercept  $(1/D_{m,CO})$  and slope  $(1/V_{c})$  can be solved. This two-step method can be time consuming and uncomfortable to perform, especially during exercise.

However, over the past 15 yrs, the measurement of diffusing capacity of the lung using the

transfer gases nitric oxide (NO) and CO together permits one to obtain Dm,CO and Vc in a singlebreath manoeuvre, thus allowing a similar distribution of the two gases and reducing the number of measurements and testing time by half [4, 5]. The velocity constant of the combination of NO with haemoglobin is about 280 times faster than that of CO [6], and thus the specific blood transfer conductance for NO ( $\Theta$ NO) is so large that the red cell resistance to NO  $(1/\Theta NO)$ approaches zero [7]. Therefore, diffusing capacity of the lung for nitric oxide (DL,NO) equals the membrane diffusing capacity for NO (Dm,NO), and is independent of Vc and haemoglobin concentration [8]. Others have made the same assumption that  $(1/\Theta NO)$  is negligible [9–14], and it was recently determined that a nonzero 1/ ΘNO would not be able to explain their experimental data [12]. Therefore, these data suggest that DL,NO is a good measure of Dm,NO. Given that the molecular weight of CO and NO are 28 and 30  $g \cdot M^{-1}$ , respectively, and solubilities (Bunsen coefficients) of CO and NO in plasma at 37°C are 0.0215 and 0.0439 [15], respectively, the diffusivity of NO, which is the solubility of NO divided by the square root of the molecular weight (MW) of NO ( $\sqrt{MWNO}$ ), is ~1.97 times AFFILIATIONS Dept of Anesthesia, McGill University Health Center, Montreal, Canada.

CORRESPONDENCE G.S. Zavorsky Dept of Anesthesia McGill University Health Center Montreal General Hospital 1650 Cedar Avenue Room D10-144 Montreal Quebec H3G 1A4 Canada Fax: 1 5149348249 E-mail: gerald.zavorsky@mcgill.ca

Received: December 12 2005 Accepted after revision: February 24 2006

European Respiratory Journal Print ISSN 0903-1936 Online ISSN 1399-3003 greater than that of CO and, thus, the theoretical factor between membrane diffusing capacities for NO and CO is:

## $(NO solubility / \sqrt{MWNO}) / (CO solubility / \sqrt{MWCO}) = 1.97$ (2)

Indeed, the solubility of either gas will depend upon the composition of the fluid that the gas has to diffuse through. If the fluid changes composition, the relative solubilities may well be different pre- and post-exercise. Nevertheless, data obtained from sick and healthy patients performing rebreathing manoeuvres suggest that the actual ratio of DL,NO to Dm,CO is ~2.42 [11, 12]. The larger ratio may be due to a higher than assumed NO solubility in plasma as well as NO facilitated diffusion [12].

Several researchers have previously obtained DL,NO from single-breath [4, 5, 9, 10, 13, 14, 16-19] or rebreathing manoeuvres [11, 12], along with the simultaneous measurement of DL,CO to obtain Dm,CO and Vc. Since brief exposure to NO does not interfere with physiological function [11, 12, 20, 21], it seems pertinent to use NO as a test gas to assess lung diffusion capacity. However, there is still debate as to whether inhalations of high NO concentrations (~40-50 ppm) during sequential single-breath manoeuvres can affect the pulmonary microcirculation. At those NO concentrations, pulmonary vasodilation may occur, increasing DL,CO, Vc and perhaps DL,NO (Dm,CO) [22]. Therefore, the first objective of the present study was to determine whether five sequential single breathhold manoeuvres inhaling ~40 ppm of NO increase DL,CO,  $DL_{NO}$  (and thus  $Dm_{,CO}$ ) and  $V_{c}$ . The current hypothesis was that five repeated inhalations of 40-50 ppm of NO would not increase DL,CO, DL,NO (Dm,CO) or Vc.

Furthermore, the recent 2005 American Thoracic Society (ATS)/European Respiratory Society (ERS) task force guidelines of standardisation of the single-breath determination of CO uptake in the lung [23] mentioned that more research is needed to determine the actual number of tests required to provide a reasonable estimate of the average  $D_{\rm L,CO}$ . Therefore, the second objective of the current study was to determine the actual number of tests required to provide a reasonable estimate of not only  $D_{\rm L,CO}$ , but  $D_{\rm L,NO}$  ( $D_{\rm m,CO}$ ) and  $V_{\rm c}$  for a given person. The present authors' hypothesis was that an average of three measurements would be needed to obtain a reasonable estimate of all those parameters.

The third objective was to determine the repeatability of lung diffusing capacity and its components over five trials in a given patient using the newer single-breath method of CO and NO. This would help to decide whether a change in an observation of *DL*,NO, *DL*,CO, *Dm*,CO and *V*c represents a real clinical change in the pulmonary system or just measurement error. The current authors' hypothesis was that the repeatability for *DL*,NO, *DL*,CO and *Dm*,CO would be 10, 2 and 6 mL·min<sup>-1</sup>·mmHg<sup>-1</sup>, respectively, and 10 mL for *V*c.

## METHODS

#### Subjects

In total, 31 healthy subjects were recruited (15 females, 16 males) and all completed the study (aged  $33\pm9$  yrs; weight  $68.6\pm12.5$  kg; height  $169.9\pm9$  cm). All subjects were nonsmokers. These subjects had normal resting spirometry function (forced expiratory volume in one second (FEV1) >80% predicted, and FEV1/forced vital capacity (FVC) >0.70) and no history of cardiopulmonary disease. Each subject was required to come into the laboratory on one occasion only.

### Single-breath apparatus and technique

Volume and gas calibration of the Ergocard and the Hyp'Air lung diffusion system (Medisoft, Dinant, Belgium) were performed prior to each testing session. The subjects breathed through a three-way pneumatic valve developed by Medisoft. A dead space washout volume of 900 mL was allowed, and an expired sample volume of 900 mL was collected. The instrument dead space was measured at 140 mL (including the mouthpiece, valve and filter dead spaces). Anatomical dead space (mL) was estimated as bodyweight in kg  $\times$  2.2 [23]. The concentrations of inspiratory gases were 0.295% CO, 9.96% He, 20.98% O<sub>2</sub> and balance N<sub>2</sub> for gas mixture one, and 1,000 ppm NO and balance N<sub>2</sub> for gas mixture two. A third mixture of 77 ppm NO and balance N<sub>2</sub> was used for calibration purposes only. For the single-breath manoeuvre, an inspiratory bag was filled with 5-8 L depending on the subject's FVC using the first two gas mixtures. Once the mixtures were injected into the inspiratory bag, the concentration of CO, He, NO, and O<sub>2</sub> were analysed simultaneously over 30 s by gas analysers. The injection of the various gas mixtures into the inspiratory bag resulted in approximate inspired concentrations of CO, He, NO and O<sub>2</sub> at 0.30%, 9%, 40 ppm and 20%, respectively. The types of gas analysers used for measuring inspired and expired gas mixtures have been reported elsewhere [13]. Inspired volume was measured, corrected for instrument and anatomical dead space, and converted to standard temperature, pressure and dry conditions. Breath-holding time was calculated using the method of JONES and MEADE [24].

#### Calculation of diffusion capacities, Dm and Vc

Diffusion capacities for NO and CO were calculated simultaneously from the exponential disappearance rate of each gas with respect to He using the method by JONES and MEADE [24]. The formulae for calculating *DL*,CO can be found in the 2005 ATS/ERS guidelines [23]. All results were standardised to a haemoglobin (Hb) concentration of 14.6 g·dL<sup>-1</sup> for males and 12.0 g·dL<sup>-1</sup> for females, and a *PA*,O<sub>2</sub> of 13.3 kPa (100 mmHg) by inserting these values into the following formula by ROUGHTON and FORSTER [1]:

$$(1/\Theta CO) = (0.73 + 0.0058 \times Po_2) \times (14.6/[Hb])$$
 (3)

where  $1/\Theta$ CO was 1.426 and  $\Theta$ CO was 0.701 mL·min<sup>-1</sup>· mmHg<sup>-1</sup> for males,  $1/\Theta$ CO was 1.594 and  $\Theta$ CO was 0.627 mL· min<sup>-1</sup>·mmHg<sup>-1</sup> for females and  $PO_2$  was partial pressure of oxygen. A *DL*,NO to *Dm*,CO ratio of 2.42 [11, 12, 14] and 1.97 [5, 9, 10, 13, 19] was used as the theoretical ratio of *DL*,NO to *Dm*,CO during single-breath manoeuvres since those ratios have both been used in the past. The ratio of 2.42 has been determined recently during rebreathing manoeuvres at rest and during exercise [11, 12], which can result in *Dm*,CO values that are more in line with the current normative values [25]. Therefore, due to the two different *DL*,NO to *Dm*,CO ratios reported in the literature, the current authors reported two different *Dm*,CO values and two different *V*<sub>c</sub> values.

A breath-holding time of 4-5 s was chosen because it has been shown that DL,CO values were not different with a 3- or 5-s

breath hold compared with a 7- and 10-s breath hold [26] and a breath-holding time of ~9 s would result in a less than detectable amount of expired NO [4]. The present authors did not account for NO back pressure in the calculations since exhaled NO concentrations at rest are negligible, ranging 11-66 ppb (0.011–0.066 ppm) [27], which tend to decrease during exercise [28]. The amount of NO back pressure then would minimally affect DL,NO calculations as the measurements were carried out in the ppm range, which is  $\sim$ 75–500 times larger than the exhaled NO concentration at rest or during exercise after a single-breath inspiration of 40–60 ppm NO. Accounting for CO back pressure is also negligible as it has been shown that 2 min between tests virtually eliminates all the CO gas from the lungs in healthy subjects [29]. As the recent ATS/ERS guidelines recommend a minimum of 4 min between DL,CO measurements [23], subjects performed the single-breath manoeuvre with a minimum of 4.5 min between tests. Five sequential diffusion capacity tests were performed.

## Statistical analyses

A one-way repeated measures ANOVA was used to determine if there were significant differences in *DL*,CO, *DL*,NO, *Dm*,CO and *V*c between the five trials. A Tukeys/Kramer *post hoc* comparison test was used to see where the differences in the five trials occurred. In addition, the variables height, age and weight were examined by forward stepwise multiple regression to determine which and what combination most predicted *DL*,NO values at rest. The measurement error for *DL*,NO, *Dm*,CO, *DL*,CO and *V*c was calculated as the square root of the residual mean square error (which is also called the within-subject standard deviation) obtained from the one-way repeated measures ANOVA [30]. The repeatability of each variable was then obtained multiplying the within-subject standard deviation by 2.77 [30]. A p-value of <0.05 was considered statistically significant.

# RESULTS

Of the 31 subjects, 29 had normal spirometry function (table 1) based on the fact that FEV1 was >80% pred for all subjects, and the FEV1/FVC was >0.7 for all but two subjects (FEV1/FVC 0.67 and 0.68, respectively). The single breath-hold manoeuvres, on the whole, were performed adequately (table 2). Breath-hold time was consistent within 0.3 s for all five trials, and the average inspired volume was always >90% of the FVC. The average alveolar volume was also maintained within 0.2 L for all trials.

The data show that DL,NO and, thus, Dm,CO remained unaltered from trial one to trial five (table 3). However, compared with the first trial, DL,CO and Vc significantly decreased by the fourth ( $-4 \pm 5\%$ ; 95% confidence interval (CI) -5--2%; p<0.05) and third trial (-5±7%; 95% CI -7--2%; p < 0.05), respectively. When  $D_{m,CO} = D_{L,NO}/2.42$ , the per cent predicted based on age, height and sex was  $111 \pm 31\%$  (range 62–164%; p<0.05), but when  $D_{m,CO}=D_{L,NO}/1.97$ , the per cent predicted was  $136 \pm 39\%$  (72–202%; p<0.05). For V<sub>c</sub>, when Dm,CO=DL,NO/2.42 the per cent predicted based on height and sex was  $116 \pm 19\%$  (76–155%; p<0.05), but when  $D_{m,CO}=$ DL,NO/1.97 the per cent predicted for Vc was  $100\pm16\%$ (66–131%; p>0.05). Therefore, when Dm,CO=DL,NO/2.42, the Dm,CO is reduced closer to normative values and the Vc is increased above normative values. The opposite occurs when Dm,CO=DL,NO/1.97 as the Dm,CO is largely increased above the predicted value, but Vc is reduced to 100% pred.

The measurement error and repeatability of five trials are presented in table 4. The repeatability represents the critical value in which a clinically measurable change in a given patient occurs between sessions. From the repeated measures ANOVA, a real clinical change in a patient's pulmonary diffusion capacity and its components was 17.2 and  $3.2 \text{ mL}\cdot\text{min}^{-1}\cdot\text{mmHg}^{-1}$  for *DL*,NO and *DL*,CO, respectively.

TABLE 1	Subject characteristics and resting spirometry				
	Mean±sɒ (range)	Predicted	% predicted		
Females n	15				
Males n	16				
Age yrs	33±9 (18–56)				
Weight kg	68.6±12.5 (49.4–98.8)				
Height cm	169.9±9.0 (155–189.5)				
BMI <sup>#</sup> kg⋅m⁻²	23.6±3.1 (18.1–30.2)				
BSA <sup>¶</sup> m <sup>2</sup>	1.77±0.19 (1.44–2.17)				
FEV1 L	3.93±0.67 (2.77–5.67)	3.73±0.61 (2.73-5.00)	106±11 (89–126)		
FVC L	4.89±0.84 (3.28–6.57)	4.54±0.81 (3.43-6.23)	109±12 (87–134)		
FEV1/FVC	0.81 ± 0.06 (0.67–0.92)				
PEF L·s <sup>-1</sup>	9.06±2.14 (5.71-13.90)	8.52±1.54 (6.49-11.33)	106±13 (84–140)		
FEF25-75 L·s <sup>-1</sup>	4.86±1.19 (2.81–8.03)	3.81±0.53 (2.74-4.77)	127±23 (87–177)*		

BMI: body mass index; BSA: body surface area; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory flow; FEF25–75: mean forced expiratory flow between 25 and 75% FVC. <sup>#</sup>: calculated at weight (kg) divided by height (m); <sup>¶</sup>: calculated as 0.0097 × (height in cm+weight in kg)-0.545. \*: predicted value significantly different than measured value (p<0.05). Pulmonary function values in males calculated as a percentage of normal values predicted for males and females of same height and age from HANKINSON *et al.* [31].

TABLE 2	Characteristics of th	ne five sequential sir	ngle breath-hold ma	noeuvres in 31 subj	ects	
Variables	Trial 1	Trial 2	Trial 3	Trial 4	Trial 5	Average of 5 trials
Breath-hold	5.5±0.6 (4.7–6.7)	5.3±0.4 (4.7–6.0)	5.3±0.5 (4.6–6.2)	5.2±0.4 (4.6-6.0)*	5.3±0.5 (4.6–6.5)	5.3±0.4 (4.7–6.0)
Inspired volume L	4.8±0.8 (3.0-6.8)	4.7±0.8 (3.0–6.5)	4.7±0.9 (2.9–6.4)	4.8±0.9 (3.0-6.8)	4.7±0.8 (3.0-6.4)	4.7±0.8 (3.0–6.6)
Inspired volume % of FVC	97.4±6.5 (80.7–108.9)	97.0±6.2 (80.1–108.7)	96.0±7.9 (77.5–109.3)	97.9±6.4 (78.0–109.8)	96.6±6.3 (76.5-109.5)	97.0±6.0 (78.6-109.2)
Alveolar volume L	6.6±1.1 (4.5–9.3)	6.5±1.1 (4.5-9.4)	6.4±1.1 (4.3–9.5)*	6.5±1.2 (4.4-9.7)	6.4±1.1 (4.4–9.4)*	6.5±1.1 (4.4–9.4)
Inspired NO concentratio	39.4±8.0 (11.8−53.1) <b>n</b>	41.2±5.9 (21.3–49.5)	44.3±3.4 (38.5–50.9)*	44.4±3.7 (31.9–49.8)*	44.9±2.7 (38.8–50.0)*	42.8±3.3 (31.7–49.4)
Expired NO concentratio	3.7±1.4 (1.4−1.0) <b>n</b>	4.0±1.2 (1.2–1.8)	4.2±1.2 (1.2-2.3)*	4.4±1.0 (1.0-2.7)*	4.4±1.1 (1.1–2.0)*	4.2±1.1 (1.1–2.2)
Inspired CO concentratio	0.28±0.00 (0.27–0.28) n	0.28±0.00 (0.27-0.28)*	0.28±0.0 (0.27–0.28)*	0.28±0.00 (0.27-0.28)*	0.28±0.00 (0.27–0.28)*	0.28±0.00 (0.27-0.28)
Expired CO concentratio	0.13±0.01 (0.10-0.15) <b>n</b>	0.13±0.01 (0.10-0.15)	0.13±0.01 (0.10-0.16)	0.13±0.01 (0.12-0.15)*	0.13±0.01 (0.11–0.16)*	0.13±0.01 (0.11–0.15)
Inspired O <sub>2</sub> concentratio	19.0±0.3 (18.2–19.4) <b>n</b>	19.1±0.1 (18.9–19.3)	19.1±0.1 (18.6–19.3)	19.1±0.1 (18.9–19.3)	19.1±0.1 (18.9–19.3)	19.1±0.1 (18.8–19.3)
Expired O <sub>2</sub> concentratio	15.0±0.7 (13.2–16.0) <b>n</b>	15.0±1.0 (11.3–16.7)	15.2±0.9 (12.6–16.8)	15.2±0.9 (12.7–16.7)	15.3±0.7 (13.7–16.7)	15.1±0.7 (13.3–16.5)
Inspired He concentratio	9.4±0.1 (9.1–9.6) <b>n</b>	9.4±0.1 (9.3–9.6)*	9.4±0.1 (9.3–9.6)*	9.4±0.1 (9.2–9.6)*	9.4±0.1 (9.3–9.6)*	9.4±0.1 (9.2–9.6)
Expired He concentration	6.3±0.4 (5.5–7.1) n	6.4±0.4 (5.6–7.2)	6.4±0.4 (5.7–7.2)	6.5±0.4 (5.6–7.2)	6.5±0.4 (5.6–7.2)*	6.4±0.4 (5.7–7.1)

Data are presented as mean  $\pm$  sD (range). FVC: forced vital capacity; NO: nitric oxide; CO: carbon monoxide; O<sub>2</sub>: oxygen; He: helium. \*: significantly different from trial one (p<0.05). The breath-hold time includes inspiration time plus apnoea time.

When  $D_{m,CO}=D_{L,NO}/2.42$ , a real clinical change for  $D_{m,CO}$ and  $V_c$  were 7.1 mm·min<sup>-1</sup>·Hg<sup>-1</sup> and 13 mL, respectively. When  $D_{m,CO}=D_{L,NO}/1.97$ , a real clinical change for  $D_{m,CO}$ and  $V_c$  was any change >8.7 mL·min<sup>-1</sup>·mmHg<sup>-1</sup> and 9.8 mL, respectively.

The variables age, weight and height were examined by forward stepwise multiple regression to predict  $D_{L,NO}$  values at rest. The only variable that appreciably affected  $D_{L,NO}$  was height. Predicted  $D_{L,NO}$  in mL·min<sup>-1</sup>·mmHg<sup>-1</sup>=2.0164 × height in cm–175.63 (r<sup>2</sup>=0.39; SEE=23.3). Adding the other two variables to the equation did not increase the coefficient of determination significantly. Therefore,  $D_{L,NO}$  at rest was best predicted by height.

#### DISCUSSION

The present study showed that repeated inhalations of 40– 50 ppm NO during single breath-hold manoeuvres does not increase *DL,NO*, *Dm,CO*, *DL,CO* or *Vc*. In fact, five sequential breath-hold manoeuvres did not change *DL,NO* and, thus, *Dm,CO*. However, *DL,CO* significantly decreased by the fourth trial, and *Vc* significantly decreased by the third trial. The drop in *DL,CO* by the fourth trial due to progressive increase in carboxyhaemoglobin was similar to that reported elsewhere [33]. As such, the data show that the actual number of tests required to provide a reasonable estimate of *DL,NO*, *DL,CO*, *Dm,CO* and *Vc* during properly performed manoeuvres is two trials. The average of the two trials should then be reported. Any more than two properly performed manoeuvres will lower *Vc*, and more than three will lower *DL,CO*. Therefore, two properly performed manoeuvres are sufficient to obtain all the components of lung diffusion capacity using the *DL,NO–DL,CO* method.

There has been some concern that NO may affect the pulmonary microcirculation due to its vasoactive properties

G.S. ZAVORSKY AND J.M. MURIAS
-------------------------------

TABLE 3 Lung c	liffusing capacity and it	is components over fiv	e sequential trials in 3	31 subjects			
Variables	<b>Predicted value</b>	Trial 1	Trial 2	Trial 3	Trial 4	Trial 5	Average of 5 trials
DL,NO mL·min <sup>-1</sup> ·mmHg <sup>-1</sup>	167 + 18 (137–206)	166+29 (115–214)	169+29 (114-222)	167 + 31 (112–214)	168+30 (110–226)	165 + 30 (108–217)	167+29 (112–217)
Dm,co	$62.4 \pm 10.6 \ (49.1 - 84.8)^{**}$	68.8±12.0 (47.3–88.6)	69.6±12.1 (47.0–91.9)	69.0±12.6 (46.3–88.4)	69.3±12.5 (45.4–93.6)	68.2±12.4 (44.8–89.8)	69.0±12.1 (46.4–89.6)
mL·min <sup>-1</sup> ·mmHg <sup>-1#</sup>							
Dm,co	$62.4 \pm 10.6 \ (49.1 - 84.8)^{**}$	84.5±14.7 (58.1–108.8)	85.5±14.8 (57.8–112.9)	84.8±15.5 (56.9–108.6)	85.2 ± 15.3 (55.7-114.9)	83.8±15.3 (55.0-110.3)	84.8±14.9 (57.0-110.0)
mL·min <sup>-1</sup> ·mmHg <sup>-11</sup>							
DL,CO mL·min <sup>-1</sup> ·mmHg <sup>-</sup>	36.5±4.1 (29-44.5)**	32.9±6.0 (23.4-49.6)	32.4±5.6 (22.1–43.7)	32.1±6.2 (21.2-47.6)	31.7±5.8 (21.2-44.1)*	31.4±5.9 (20.8-41.9)*	32.1±5.8 (21.7-45.4)
Ve mL⁺	75±8 (63-97)**	91 ± 16 (59–149)	87±13 (56–120)	87 ± 16 (59–143)*	84±12 (57–116)*	83±13 (50–109)*	86±13 (58-127)
Vc mL <sup>§</sup>	75±8 (63-97)	77 ± 12 (51–120)	75±10 (49–100)	74±12 (51–115)*	73±10 (50–98)*	72 ± 10 (52–92)*	74 ± 11 (50-105)
Data are presented as m	ann - Concelland - C	diffusion capacity for pitric	oxide: Dm.co: alveolar men	nhrane diffusing canacity f	or carbon monoxide: // co	o: lina diffusina canacity	for carbon monoxide. Vc.
pulmonary capillary blood	t volume. *: when Dm,co=DL	No/2.42; <sup>1</sup> : when Dm,co=DL	No/1.97; <sup>+</sup> : when <i>D</i> m,co= <i>D</i>	LNO/2.42; <sup>\$</sup> : when Dm,co=	DL,NO/1.97. *: significantly	different from trial one (p<	c0.05); **: predicted value
significantly different fro	m the measured value ave	eraged over five trials (p <c< th=""><th>).05). Predicted Dm,co val</th><th>lues are from Zanen et a</th><th>al. [25] and are reported</th><th>as mL·min<sup>-1</sup>·mmHg<sup>-1</sup>.</th><th><sup>-</sup>or males, <math>D_{m,CO}=3 \times 1/</math></th></c<>	).05). Predicted Dm,co val	lues are from Zanen et a	al. [25] and are reported	as mL·min <sup>-1</sup> ·mmHg <sup>-1</sup> .	<sup>-</sup> or males, $D_{m,CO}=3 \times 1/$
(0.127+0.0003304 × age-	0.04753 × height in m); for fe	males, Dm,co=3 × 1/(0.111+0	0.0003304 × age-0.04753 ×	height in m). Predicted DL	.co=0.41 × height in cm-0	$.21 \times age-26.31$ (r <sup>2</sup> =0.60;	SEE=4.8) from CRAPO and
Monana Fool V/ Fool anana	from Zauch of of [OE] For w	0100 1/	theight in militar familie		icht in m) Drodiotod Di vio	in minimum land	HEA hoidht in am 17E 60

For SI units (mmol·min<sup>-1</sup>·kPa<sup>-1</sup>), divide by

The units reported are traditional (mL·min<sup>-1</sup>·mmHg<sup>-1</sup>).

(r<sup>2</sup>=0.39; see=23.3) from the current study.

TABLE 4	Measurement error and repeatability of lung diffusing capacity and its components for 31 subjects			
Variable		Measurement error#	Repeatability <sup>¶</sup>	
<i>D</i> ∟,NO mL∙mir	n <sup>-1</sup> ·mmHg <sup>-1</sup>	6.2	17.2	
Dm,C0 mL·min <sup>-1</sup> ·mmHg <sup>-1+</sup> Dm,C0 mL·min <sup>-1</sup> ·mmHg <sup>-1§</sup>		2.6 3.2	7.1 8.7	
DL,CO mL·min <sup>-1</sup> ·mmHg <sup>-1</sup>		1.2	3.2	
Vc mL⁺		4.7	13.0	
Vc mL⁵		3.5	9.7	

DL,NO: diffusing capacity of the lung for nitric oxide;  $D_{m,CO}$ : membrane diffusing capacity for carbon monoxide;  $D_{L,CO}$ : diffusing lung capacity for carbon monoxide. <sup>#</sup>: within-subject standard deviation for each variable was calculated as the square root of the mean squares error from the ANOVA summary table [30]; <sup>¶</sup>: calculated as 2.77 × within-subject standard deviation [30]; <sup>+</sup>: when  $D_{m,CO}=D_{L,NO}/2.42$ ; <sup>§</sup>: when  $D_{m,CO}=D_{L,NO}/1.97$ . Each variable was reported to the nearest tenth decimal place.

[22]. One study showed that there is a small nonsignificant increase in *DL*,CO in the presence of NO [17]. However, the current authors have shown that brief exposure to NO does not interfere with physiological function. Other human [11, 12, 20, 21] and animal studies [34] are in agreement with the present study. Rebreathing 20–40 ppm NO over 16 s to 10 min resulted in no significant changes to oxygen uptake, arterial oxygen tension, alveolar–arterial oxygen tension difference, *DL*,CO, *D*m or *V*c in sick and healthy subjects at rest or during exercise [11, 12, 21]. In mechanically ventilated rabbits, *DL*,NO values remained unchanged despite inspiratory NO concentrations varying from 10–800 ppm [34]. Furthermore, the pulmonary toxicity of inhaled NO at concentrations of ~40 ppm over a prolonged period of time is minimal [35].

There is concern that different  $PA,O_2$  may slightly alter DL,NO [36]. However, more recent data has shown that varying the  $PA,O_2$  in those with or without pulmonary disease does not affect DL,NO [11, 12], implying that the combined DL,NO-DL,CO method can be used in hypoxaemic patients. Therefore, taken together, there is no reason to refrain from using NO and CO concurrently as a test gas to assess lung diffusion capacity.

The clinical implication of using both NO and CO concurrently in research and medical practice is that scientists and clinicians can immediately partition and quantify the components of lung diffusing capacity in a subject from a single 4-s breathhold manoeuvre that requires minimal effort on the part of the patient, while simultaneously being able to pinpoint which component (Vc, Dm) is causing low (or high) total lung diffusion capacities. The ability to estimate Dm,CO and Vc from one-step simultaneous measurement of DL,NO and DL,CO represents significant conceptual advantages. One conceptual advantage of the DL,NO technique is that with the standard Roughton-Forster method, cardiac output can vary between measurements of DL,CO at different O2 tensions, which then have to be interpolated to obtain DL,CO at two O2 tensions, but at the same cardiac output [12]. With the DL,NO method, all measurements are obtained at the same cardiac output and O<sub>2</sub> tension; no interpolation is necessary. Another conceptual

advantage is that with the traditional method, the distribution of CO gas in the lungs may be different at two different  $O_2$ tensions, but with the *DL*,NO method only one inspiration is required, which results in a similar distribution of NO and CO gases. A third conceptual advantage is that with the traditional method, there is systematic underestimation of *V*<sub>c</sub> and an overestimation of *D*<sub>m</sub> since the inspiration at two different  $O_2$ tensions affects alveolar–capillary membrane diffusion [37]. The *DL*,NO–*DL*,CO method avoids this error altogether and should improve the accuracy of estimated *D*<sub>m</sub>,CO and *V*<sub>c</sub>.

The ratio Dm,CO=DL,NO/2.42 gives a better estimate of Dm. When the present measured values were compared against the published norms, using the traditional two-step Roughton–Forster method [25], the predicted Dm,CO was 136% pred when Dm,CO=DL,NO/1.97, but only 111% pred when Dm,CO=DL,NO/2.42. However, the better per cent predicted values for  $V_c$  occurred when Dm,CO=DL,NO/1.97. Nonetheless, since the traditional Roughton–Forster method underestimates  $V_c$ , the current authors feel that the predicted  $V_c$  values by ZANEN *et al.* [25] slightly underestimate  $V_c$ . Therefore, the best compromise is to estimate Dm and  $V_c$  from a single breath using the DL,NO-DL,CO method and the formula Dm,CO=DL,NO/2.42.

It was also important to clarify the repeatability of lung diffusion capacity and its components over five trials from the single-breath DL,NO-DL,CO method. The repeatability allows clinicians to identify a true clinically meaningful change from measurement error. The difference between any two measurements for the same subject is expected to be <2.77 multiplied by the within-subject standard deviation; therefore, the repeatability was defined as 2.77 multiplied by the withinsubject standard deviation obtained from the ANOVA [30]. Table 4 shows a true measurable clinical change in DLNO and DL,CO as an absolute change of >17 and 3 mL·min<sup>-1</sup>·mmHg<sup>-1</sup>, respectively. In addition, a true clinical change in Dm,CO and  $V_c$  is an absolute change of >7 mL·min<sup>-1</sup>·mmHg<sup>-1</sup> and 13 mL, respectively. Any change that is less than these values is considered a true measurement error. Indeed, Dm,CO equals DLNO divided by a fixed value, and Vc is derived from the DL,NO and DL,CO; therefore the repeatability of Dm and Vc can be calculated from (or explained by) the repeatability of the DL,NO.

Based on ATS and ERS criteria, the average value of two trials whose difference in diffusing capacity is within 10% of each other is considered acceptable. The present authors looked at the average DL,NO and DL,CO for all 31 subjects over five trials, and the repeatability data of this study are in agreement with the ATS/ERS guidelines as DL,NO (and thus Dm,CO) and DL,CO are found to be 10%. However, since the variability of the parameters DL,NO and DL,CO were independent of the magnitude of the measurement, the results invalidate the use of percentage value to describe the repeatability. Using a percentage will lead to underestimation of variability in low values and overestimation for high values. Others studies have also suggested using an absolute value rather than a percentage, since the diffusing capacity was also independent of the magnitude of the measurement [38, 39]. Therefore, the current authors recommend using an absolute difference rather than a percentage as alternative criteria for repeatability. It is also recommended to report the average of two trials when

the absolute difference between the two measurements is within 17 mm·min<sup>-1</sup>·mmHg<sup>-1</sup> for DL,NO, 3 mm·min<sup>-1</sup>·mmHg<sup>-1</sup> for DL,CO, and 13 mL for  $V_c$ .

It is believed that the present paper is the first to actually quantify important measurable clinical changes in the parameters obtained from the single-breath *DL*,NO–*DL*,CO method.

### Conclusion

Small amounts of nitric oxide inhaled during sequential singlebreath manoeuvres have no effect on lung diffusing capacity for nitric oxide and, thus, membrane diffusing capacity for carbon monoxide. The recommended ratio is membrane diffusing capacity for carbon monoxide=lung diffusing capacity for nitric oxide/2.42. As more than two and three singlebreath manoeuvres will lower pulmonary capillary blood volume and lung diffusing capacity for carbon monoxide, respectively, the average value of the first two trials are recommended to provide a reasonable estimate of lung diffusing capacity for nitric oxide, lung diffusing capacity for carbon monoxide, membrane diffusing capacity for carbon monoxide and pulmonary capillary blood volume.

#### REFERENCES

- **1** Roughton FJW, Forster RE. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. *J Appl Physiol* 1957; 11: 290–302.
- **2** Hsia CC. Recruitment of lung diffusing capacity: update of concept and application. *Chest* 2002; 122: 1774–1783.
- **3** Hughes JM. The single breath transfer factor (Tl,co) and the transfer coefficient (Kco): a window onto the pulmonary microcirculation. *Clin Physiol Funct Imaging* 2003; 23: 63–71.
- **4** Borland CD, Higenbottam TW. A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. *Eur Respir J* 1989; 2: 56–63.
- **5** Guenard H, Varene N, Vaida P. Determination of lung capillary blood volume and membrane diffusing capacity in man by the measurements of NO and CO transfer. *Respir Physiol* 1987; 70: 113–120.
- **6** Meyer M, Piiper J. Nitric oxide (NO), a new test gas for study of alveolar-capillary diffusion. *Eur Respir J* 1989; 2: 494–496.
- 7 Johnson RL Jr, Heigenhauser GJF, Hsia CCW, Jones NL, Wagner PD. Determinants of gas exchange and acidbalance during exercise. *In*: Rowell LB, Shepard JT, eds. Handbook of Physiology. Section 12: Exercise: Regulation and Integration of Multiple Systems. New York, Oxford University Press, 1996; pp. 515–584.
- **8** van der Lee I, Zanen P, Biesma DH, van den Bosch JM. The effect of red cell transfusion on nitric oxide diffusing capacity. *Respiration* 2005; 72: 512–516.
- **9** Manier G, Moinard J, Stoicheff H. Pulmonary diffusing capacity after maximal exercise. *J Appl Physiol* 1993; 75: 2580–2585.

- 10 Manier G, Moinard J, Techoueyres P, Varene N, Guenard H. Pulmonary diffusion limitation after prolonged strenuous exercise. *Respir Physiol* 1991; 83: 143–153.
- **11** Tamhane RM, Johnson RL Jr, Hsia CC. Pulmonary membrane diffusing capacity and capillary blood volume measured during exercise from nitric oxide uptake. *Chest* 2001; 120: 1850–1856.
- **12** Phansalkar AR, Hanson CM, Shakir AR, Johnson RL Jr, Hsia CC. Nitric oxide diffusing capacity and alveolar microvascular recruitment in sarcoidosis. *Am J Respir Crit Care Med* 2004; 169: 1034–1040.
- **13** Zavorsky GS, Quiron KB, Massarelli PS, Lands LC. The relationship between single-breath diffusion capacity of the lung for nitric oxide and carbon monoxide during various exercise intensities. *Chest* 2004; 125: 1019–1027.
- **14** Zavorsky GS, Lands LC. Lung diffusion capacity for nitric oxide and carbon monoxide is impaired similarly following short-term graded exercise. *Nitric Oxide* 2005; 12: 31–38.
- **15** Roughton FJH, Gibson QH. The kinetics and equilibrium reactions of nitric oxide with sheep hemoglobin. *J Physiol* 1957; 136: 507–526.
- **16** Moinard J, Guenard H. Determination of lung capillary blood volume and membrane diffusing capacity in patients with COLD using the NO-CO method. *Eur Respir J* 1990; 3: 318–322.
- **17** Tsoukias NM, Dabdub D, Wilson AF, George SC. Effect of alveolar volume and sequential filling on the diffusing capacity of the lungs: II. Experiment. *Respir Physiol* 2000; 120: 251–271.
- 18 Perillo IB, Hyde RW, Olszowka AJ, et al. Chemiluminescent measurements of nitric oxide pulmonary diffusing capacity and alveolar production in humans. J Appl Physiol 2001; 91: 1931–1940.
- **19** Vaida P, Kays C, Riviere D, Techoueyres P, Lachaud JL. Pulmonary diffusing capacity and pulmonary capillary blood volume during parabolic flights. *J Appl Physiol* 1997; 82: 1091–1097.
- **20** Brett SJ, Chambers J, Bush A, Rosenthal M, Evans TW. Pulmonary response of normal human subjects to inhaled vasodilator substances. *Clin Sci (Lond)* 1998; 95: 621–627.
- **21** Sheel AW, Edwards MR, Hunte GS, McKenzie DC. Influence of inhaled nitric oxide on gas exchange during normoxic and hypoxic exercise in highly trained cyclists. *J Appl Physiol* 2001; 90: 926–932.
- **22** van der Lee I, Zanen P. Diffusion capacity for nitric oxide and carbon monoxide. *Chest* 2004; 126: 1708–1709, author reply 1709–1710.
- **23** Macintyre N, Crapo RO, Viegi G, *et al.* Standardisation of the single-breath determination of carbon monoxide uptake in the lung. *Eur Respir J* 2005; 26: 720–735.
- **24** Jones RS, Meade F. A theoretical and experimental analysis of anomalies in the estimation of pulmonary diffusing

capacity by the single breath method. *Q J Exp Physiol* 1961; 46: 131–143.

- **25** Zanen P, van der Lee L, van der Mark T, van den Bosch JM. Reference values for alveolar membrane diffusion capacity and pulmonary capillary blood volume. *Eur Respir J* 2001; 18: 764–769.
- **26** Turcotte RA, Perrault H, Marcotte JE, Beland M. A test for the measurement of pulmonary diffusion capacity during high-intensity exercise. *J Sports Sci* 1992; 10: 229–235.
- **27** Iwamoto J, Pendergast DR, Suzuki H, Krasney JA. Effect of graded exercise on nitric oxide in expired air in humans. *Respir Physiol* 1994; 97: 333–345.
- **28** Pogliaghi S, Krasney JA, Pendergast DR. Effect of gravity on lung exhaled nitric oxide at rest and during exercise. *Respir Physiol* 1997; 107: 157–164.
- **29** Ogilvie CM, Forster RE, Blakemore WS, Morton JW. A standardized breathholding technique for the clinical measurement of diffusing capacity for the lung for carbon monoxide. *J Clin Invest* 1957; 36: 1–17.
- **30** Bland JM, Altman DG. Measurement error. *BMJ* 1996; 313: 744.
- **31** Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999; 159: 179–187.
- **32** Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. *Am Rev Respir Dis* 1981; 123: 185–189.
- **33** Frey TM, Crapo RO, Jensen RL, Elliott CG. Diurnal variation of the diffusing capacity of the lung: is it real? *Am Rev Respir Dis* 1987; 136: 1381–1384.
- **34** Heller H, Schuster KD. Single-breath diffusing capacity of NO independent of inspiratory NO concentration in rabbits. *Am J Physiol* 1997; 273: R2055–R2058.
- **35** Hugod C. Effect of exposure to 43 ppm nitric oxide and 3.6 ppm nitrogen dioxide on rabbit lung. A light and electron microscopic study. *Int Arch Occup Environ Health* 1979; 42: 159–167.
- **36** Borland CD, Cox Y. Effect of varying alveolar oxygen partial pressure on diffusing capacity for nitric oxide and carbon monoxide, membrane diffusing capacity and lung capillary blood volume. *Clin Sci* (*Colch*) 1991; 81: 759–765.
- **37** Hsia CC, Chuong CJ, Johnson RL Jr. Critique of conceptual basis of diffusing capacity estimates: a finite element analysis. *J Appl Physiol* 1995; 79: 1039–1047.
- **38** Robson AG, Innes JA. Short term variability of single breath carbon monoxide transfer factor. *Thorax* 2001; 56: 358–361.
- **39** Punjabi NM, Shade D, Patel AM, Wise RA. Measurement variability in single-breath diffusing capacity of the lung. *Chest* 2003; 123: 1082–1089.